State Street Corp. Updates Passive Stake in Nurix Therapeutics
Ticker: NRIX · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 1549595
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**State Street still owns Nurix stock, it's a passive investment.**
AI Summary
State Street Corporation, a major financial institution, filed an amended Schedule 13G/A on January 23, 2024, indicating its ownership of Nurix Therapeutics, Inc. common stock as of December 31, 2023. This filing updates their previous disclosure, confirming their continued passive investment in the pharmaceutical company. For investors, this means a large institutional investor maintains a position in Nurix, which can signal confidence but also means a significant block of shares could be sold if State Street changes its strategy.
Why It Matters
This filing shows that a major institutional investor, State Street Corporation, continues to hold a significant, passive stake in Nurix Therapeutics, Inc., which can influence market perception and liquidity.
Risk Assessment
Risk Level: low — This is a routine update from a large institutional investor, indicating a passive stake, which generally poses low risk to the company or its shareholders.
Analyst Insight
Investors should note that a major institution holds a passive stake, indicating a long-term, non-activist interest. This filing itself doesn't suggest immediate action but confirms institutional presence.
Key Numbers
- 67080M103 — CUSIP Number (identifies Nurix Therapeutics, Inc. common stock)
- 04-2456637 — IRS Identification No. (identifies State Street Corporation)
- 005-91591 — SEC File Number (identifies Nurix Therapeutics, Inc. with the SEC)
Key Players & Entities
- State Street Corporation (company) — the reporting person and institutional investor
- Nurix Therapeutics, Inc. (company) — the subject company whose stock is being reported
- 0000093751-24-000095 (dollar_amount) — accession number for the filing
- December 31, 2023 (date) — date of event requiring the filing
- January 23, 2024 (date) — date the filing was made
Forward-Looking Statements
- State Street Corporation will likely maintain a passive investment strategy in Nurix Therapeutics for the foreseeable future. (State Street Corporation) — high confidence, target: 12/31/2024
- Nurix Therapeutics' stock price will not experience significant volatility directly due to this routine filing. (Nurix Therapeutics, Inc.) — high confidence, target: 02/23/2024
FAQ
Who filed this SC 13G/A statement?
The SC 13G/A statement was filed by State Street Corporation, as indicated in the 'FILED BY' section and 'NAME OF REPORTING PERSON' on page 2 of 5.
What is the subject company of this filing?
The subject company, or 'NAME OF ISSUER,' is Nurix Therapeutics Inc., as stated on the first page of the Schedule 13G.
What type of securities are covered by this filing?
The filing covers 'COMMON STOCK' of Nurix Therapeutics Inc., as specified under 'TITLE OF CLASS OF SECURITIES' on the Schedule 13G.
What was the date of the event that required this filing?
The 'DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT' was 12/31/2023, as noted on the Schedule 13G cover page.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under 'RULE 13D-1 (B)', as indicated by the checked box on the cover page of the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding Nurix Therapeutics, Inc. (NRIX).